Imatinib Mesylate in Treating Patients With Recurrent Meningioma
Public ClinicalTrials.gov record NCT00045734. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent meningioma. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
Study identification
- NCT ID
- NCT00045734
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- imatinib mesylate Drug
- laboratory biomarker analysis Other
- pharmacological study Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2003
- Primary completion
- Nov 30, 2009
- Completion
- Nov 30, 2009
- Last update posted
- May 14, 2017
2003 – 2009
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| University of California San Francisco | San Francisco | California | 94115 | — |
| National Cancer Institute Neuro-Oncology Branch | Bethesda | Maryland | 20814 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75235 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00045734, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2017 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00045734 live on ClinicalTrials.gov.